Floatz logo

Cyclophosphamide

SMARCA4 Gene Mutation

Prelude TherapeuticsSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the SMARCA4 Gene Mutation cohort.

Asset / SponsorPhaseRating
prt3789
Prelude Therapeutics
Phase 2B
Epirubicin
Prelude Therapeutics
Phase 2CCC
Pembrolizumab
Prelude Therapeutics
Phase 2CCC
Docetaxel
Prelude Therapeutics
Phase 1CC

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →